Epstein Files

EFTA02617028.pdf

dataset_11 pdf 291.4 KB Feb 3, 2026 6 pages
From: Boris Nikolic < Sent: Saturda , November 3, 2018 11:15 PM To: Cc: jeevacation@gmail.com Subject: RE: Re: Hi Harry Please let me double check this. There are many projects that BMGF specifically do not fund directly (especially if it has to do with a delivery, procurement etc) but through partners such as PATH, PSI etc. There are some projects that BMGF funded a lot such a male circumcision but got eventually transferred to the partners. It will take me few days to find out as I do not know the new director of Reproductive Health (they changed few since I left!) and strangely RH is a part of global development (not a Global Health). Please ping me in a week or so. Best Boris From: Sent: Saturday, November 3, 2018 2:32 PM To: Boris Nikolic < Cc: jeevacation@gmail.com Subject: Re: Hi Boris Currently The Female Health division of VERU supplies approximately SO million Female Condoms worldwide. BMGF has never funded the FC2 Female condom. I don't know why this is the case. EFTA_R1_01818211 EFTA02617028 The FC2 female condom is the most demanded and utilized female condom worldwide. It is supplied throughout Africa via UNFPA and bought directly by South Africa. Funding by UNFPA has dramatically decreased and we are unable to supply certain countries that have requested the female condom. For example, the following countries have requested the FC2 female condom but we are unable to supply: Uganda : 3 million units Ghana: 1 million units Botswana: 1 million units Tunesia: 1 million units Sierra Leone: 500,000 units Bolivia: 500,000 units Tanzania: 1 million units Haiti: 500,000 units Ethiopia: 1 million units Congo DR: 2 million units Boris, can you introduce me to the right person at BMGF to see if we can get grants to provide FC2 female condoms to all women who request them in Africa. Also attached is more information regarding the FC2 female condom. Would like to continue the conversation. Sincerely, Harry 2 EFTA_R1_01818212 EFTA02617029 Original Message From: Boris Nikolic < <mailto >> To: harryfisch < <mailto >> > Cc: jeevacation <jeevacation@gmail.com <mailto:jeevacation@gmail.com» Sent: Sat, Nov 3, 2018 1:27 pm Subject: RE: Re: Thank you Harry! Again — great meeting you. I am still laughing re inherited STD. Finally I had chance to read your slide deck. VERU is indeed very interesting company — congrats! You have an interesting mix of Urology specialty drugs (which I see as a low risk) and Prostate cancer drugs. Unfortunately my fund (https://www.biomaticscapital.com/) is only focused (and restricted to investing) on private companies. Mid-end of the next year I am going to fundraise a crossover fund which would allow me to invest in both private and publicly listed companies; nevertheless, I am now unable to invest in companies such as VERU — despite how interesting they might be. I looked at a female condom. I think that PATH supported a number of related projects. https://www.path.oreartides/seven-secrets-of-the-female-condom/ <https://www.path.org/articles/seven-secrets-of- the-female-condomh As you might know BMGF is the main donor to PATH — this is why I mentioned it. Also BMGF founded several smaller grants (GCE) re female condoms https://www.gatesfoundation.org/Media- Center/Press-Releases/2014/06/GCE-Round-12 <https://www.gatesfoundation.org/Media-Center/Press- Releases/2014/06/GCE-Round-12> In addition, there were grants to Imperial College in London, HealthRock etc. All of these are relatively old grants that ended. My guess is that all female condom more mature projects transitioned to PATH. Also I see that PSI has been funding marketing and delivery https://www.psi.org/2018/03/fresh-start-female-condom- marketing/ <https://www.psi.org/2018/03/fresh-start-female-condom-marketing/> 3 EFTA_R1_01818213 EFTA02617030 Please let me know if there is anything else I can be of help to you. Hope to see you soon in NYC Best Boris From: <mailto > < <mailto >> Sent: Thursday, November 1, 2018 5:34 PM To: Boris Nikolit < <mailto >>; jeevacation@gmail.com <mailto:jeevacation@gmail.com> Subject: Re: Jeffrey thanks for introducing me to Boris. Boris, great meeting you as well. Attached is the most recent deck for VERU (NASDAQ: VERU), www.verupharma.com <http://www.verupharma.com> . In addition please look at www.femalecondom.com <http://www.femalecondom.com> . We merged with The Female Health Company which sells the FC2 Female Condom to the public sector in Africa and Brazil via UNFPA and USAID. We just recently introduced this condom into the US market mainly via telemedicine. Would love to meet and discuss further. Sincerely, 4 EFTA_R1_01818214 EFTA02617031 Harry Harry Fisch MD cell Original Message From: Boris Nikolic < <mailto >> To: .1 <jeevacation@gmail.com <mailto:jeevacation@gmail.com»; Harry Fisch < <mailto: > Sent: Thu, Nov 1, 2018 4:13 pm Subject: RE: Thank you J! Great meeting you Harry! Looking forward to seeing you again. Please send me something re your company. Best Boris From: J <jeevacation@gmail.com <mailto:jeevacation@gmail.com» Sent: Thursday, November 1, 2018 3:15 PM To: Boris Nikolic < <mailto »; Harry Fisch <mailto-> > Subject: harry boris , boris harry please note The information contained in this communication is 5 EFTA_R1_01818215 EFTA02617032 confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to jeevacation@gmail.com <mailtcyjeevacation@gmail.com> , and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved 6 EFTA_R1_01818216 EFTA02617033

Entities

0 total entities mentioned

No entities found in this document

Document Metadata

Document ID
01951282-4b97-451b-a8e2-9d4269282088
Storage Key
dataset_11/EFTA02617028.pdf
Content Hash
bda92dd5a86f8db4165e60b498213b23
Created
Feb 3, 2026